دورية أكاديمية
أعرض في EDS

Adoption and uptake of the lateral flow urine LAM test in countries with high tuberculosis and HIV/AIDS burden: current landscape and barriers.

التفاصيل البيبلوغرافية
العنوان: Adoption and uptake of the lateral flow urine LAM test in countries with high tuberculosis and HIV/AIDS burden: current landscape and barriers.
المؤلفون: Singhroy DN; McGill International TB Centre, McGill University, Montreal, QC, H4B1X5, Canada., MacLean E; McGill International TB Centre, McGill University, Montreal, QC, H4B1X5, Canada.; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada., Kohli M; McGill International TB Centre, McGill University, Montreal, QC, H4B1X5, Canada., Lessem E; Department of Tuberculosis, Treatment Action Group, New York, NY, USA., Branigan D; Department of Tuberculosis, Treatment Action Group, New York, NY, USA., England K; Independent Consultant, Los Angeles, CA, USA., Suleiman K; Independent Consultant, Istanbul, Turkey., Drain PK; Departments of Global Health, Medicine, and Epidemiology, University of Washington, Seattle, WA, USA., Ruhwald M; Department of Tuberculosis, Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland., Schumacher S; Department of Tuberculosis, Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland., Denkinger CM; Division of Tropical Medicine, Center of Infectious Diseases, University of Heidelberg, Heidelberg, Germany., Waning B; Stop TB Partnership, Global Drug Facility, Geneva, Geneva, Switzerland., Van Gemert W; Stop TB Partnership, Global Drug Facility, Geneva, Geneva, Switzerland., Pai M; McGill International TB Centre, McGill University, Montreal, QC, H4B1X5, Canada.; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada.
المصدر: Gates open research [Gates Open Res] 2020 Apr 07; Vol. 4, pp. 24. Date of Electronic Publication: 2020 Apr 07 (Print Publication: 2020).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Bill and Melinda Gates Foundation Country of Publication: United States NLM ID: 101717821 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-4754 (Electronic) Linking ISSN: 25724754 NLM ISO Abbreviation: Gates Open Res Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Seattle, WA : Bill and Melinda Gates Foundation, [2017]-
مستخلص: Background: Since 2015, the World Health Organization (WHO) has recommended a commercially available lateral-flow urine LAM test (Alere-LAM) to assist in the diagnosis of tuberculosis (TB) in severely ill people living with HIV (PLHIV). The test can rapidly detect TB in severely ill PLHIV and can identify PLHIV most at-risk of death, leading to mortality reductions. However, its uptake in countries with high burdens of TB and HIV has been slow. To assess the current use landscape and identify barriers to the adoption of Alere-LAM, we conducted a questionnaire-based study in 31 high TB and HIV/AIDS burden countries. Methods : Between November 2018 and December 2019, we collected responses to a semi-structured questionnaire that had been emailed to staff and affiliates of National TB Programs or HIV/AIDS Programs, Ministries of Health, and TB or HIV institutes of 31 high TB/HIV burden countries. Questions concerned country policies, adoption, and current use of Alere-LAM testing, as well as testing algorithms and barriers preventing Alere-LAM uptake. Results: We received questionnaire responses from 24 out of 31 (77%) high TB/HIV burden countries. Of these 24 countries, 11 (46%) had adopted Alere-LAM policies, with only five (21%) countries currently using Alere-LAM testing. Testing algorithms were generally aligned with WHO recommendations. Fifteen countries (63%) said they were planning to implement Alere-LAM testing in the near future. The most commonly cited constraint to adoption and implementation was budget limitations. Additional barriers to Alere-LAM implementation included lack of country-specific data and piloting, administrative hurdles such as regulatory agency approval, lack of coordination between National TB and HIV programs, and small perceived patient population. Conclusion: Responses to our questionnaire demonstrate the persistent gap between country-level policy and real-world use of Alere-LAM, as well as specific barriers that must be addressed to scale-up testing in PLHIV.
Competing Interests: Competing interests: MR and SS are employed by FIND. FIND is a not-for-profit NGO that collaborates in partnerships to develop, evaluate and implement new diagnostics for LMIC. FIND has product evaluation agreements with several private sector companies that design diagnostics and related products for treatment of tuberculosis and other diseases. These agreements strictly define FIND’s independence and neutrality vis-a-vis the companies whose products get evaluated and describe roles and responsibilities. CMD previously worked at FIND, Geneva. MP previously consulted for the Bill & Melinda Gates Foundation. He serves on the Scientific Advisory Committee of FIND, Geneva. KE is an advisor for Fujifilm which is developing a next generation LAM test. The other authors have no conflicts to disclose.
(Copyright: © 2020 Singhroy DN et al.)
References: J Clin Med. 2019 Dec 31;9(1):. (PMID: 31906163)
J Infect Dis. 2017 Nov 6;216(suppl_7):S702-S713. (PMID: 29117342)
AIDS. 2015 Sep 24;29(15):1987-2002. (PMID: 26266773)
J Int AIDS Soc. 2016 Jan 12;19(1):20714. (PMID: 26765347)
BMC Med. 2017 Mar 21;15(1):67. (PMID: 28320384)
Lancet Infect Dis. 2012 Mar;12(3):201-9. (PMID: 22015305)
Eur Respir J. 2016 Aug;48(2):516-25. (PMID: 27418550)
Lancet Infect Dis. 2019 Aug;19(8):852-861. (PMID: 31155318)
J Clin Microbiol. 2018 Nov 27;56(12):. (PMID: 30257899)
Lancet Infect Dis. 2018 Jan;18(1):76-84. (PMID: 29198911)
AIDS. 2009 Sep 10;23(14):1875-80. (PMID: 20108382)
Sci Transl Med. 2017 Dec 13;9(420):. (PMID: 29237757)
J Microbiol Methods. 2001 May;45(1):41-52. (PMID: 11295196)
Lancet. 2018 Jul 28;392(10144):292-301. (PMID: 30032978)
Diagnostics (Basel). 2018 Nov 23;8(4):. (PMID: 30477096)
Clin Infect Dis. 2018 Mar 4;66(suppl_2):S111-S117. (PMID: 29514238)
Lancet. 2016 Mar 19;387(10024):1187-97. (PMID: 26970721)
Lancet. 2007 Jun 16;369(9578):2042-2049. (PMID: 17574096)
Cochrane Database Syst Rev. 2019 Oct 21;10:CD011420. (PMID: 31633805)
BMC Med. 2016 Mar 23;14:53. (PMID: 27007773)
فهرسة مساهمة: Keywords: LAM; barriers; lipoarabinomannan; policy; rapid testing; tuberculosis; urine
تواريخ الأحداث: Date Created: 20200416 Latest Revision: 20210110
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC7059561
DOI: 10.12688/gatesopenres.13112.2
PMID: 32185366.2. Version: 2. Publisher Version ID: 2. Version Date: 2020/04/07
قاعدة البيانات: MEDLINE
الوصف
تدمد:2572-4754
DOI:10.12688/gatesopenres.13112.2